Published in Hepat Med on May 27, 2014
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
The global burden of hepatitis C. Liver Int (2009) 8.89
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med (2007) 5.83
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med (2005) 4.79
Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med (1994) 4.09
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol (2013) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
The natural history of hepatitis C virus (HCV) infection. Int J Med Sci (2006) 3.13
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol (2011) 3.11
AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology (2005) 2.90
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87
Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology (2012) 2.59
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol (2010) 2.43
Hepatitis C virus resistance to protease inhibitors. J Hepatol (2011) 2.18
The natural history of hepatitis C. Semin Liver Dis (2004) 1.95
Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis (2003) 1.93
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology (2013) 1.84
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology (2012) 1.76
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35
Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int (2011) 1.31
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog (2012) 1.30
Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat (1999) 1.25
Maternal-infant transmission of hepatitis C virus infection. Hepatology (2002) 1.23
The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology (1996) 1.19
High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dis (2003) 1.12
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis (2011) 1.08
Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat (2013) 1.01
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology (2011) 1.00
Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol (2012) 0.99
HCV therapy in HIV-infected patients. Liver Int (2013) 0.96
High prevalence of hepatitis C virus genotype 1b infection in a small town of Argentina. Phylogenetic and Bayesian coalescent analysis. PLoS One (2010) 0.93
[Distribution of the genotypes of hepatitis C virus in intravenous drug addicts in Argentina]. Medicina (B Aires) (1999) 0.89
Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. HIV Med (2013) 0.89
Safety of direct antiviral agents in real life. Dig Liver Dis (2013) 0.88
Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies. Liver Int (2012) 0.88
Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol (2011) 0.87
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J Hepatol (2013) 0.87
Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Ann Hepatol (2010) 0.85
HCV genotype distribution among HIV co-infected individuals in Argentina: relationship with host and viral factors. Acta Gastroenterol Latinoam (2007) 0.84
High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina. Liver Int (2006) 0.84
Hepatitis C virus infection in infants and children from Argentina. J Clin Microbiol (2004) 0.84
How to optimize HCV therapy in genotype 2 patients. Liver Int (2013) 0.82
Hepatitis C and HIV coinfection in central region of Argentina: prevalence, genotype characterization and risk factors. Enferm Infecc Microbiol Clin (2008) 0.81
New antiviral therapies in the management of HCV infection. Antivir Ther (2012) 0.81
Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjects. Ann Hepatol (2012) 0.80
A clustering phenomenon among HCV-1a strains among patients coinfected with HIV from Buenos Aires, Argentina. J Med Virol (2012) 0.78
Update on the treatment of patients with non-genotype 1 hepatitis C virus infection. Clin Infect Dis (2012) 0.78
Risk factors for infection in chronic hepatitis C: a high prevalence of sexual exposure among human immunodeficiency virus-coinfected women. Hepatology (2011) 0.78
[Statement of the Argentinian Concensus on Hepatitis C 2007]. Acta Gastroenterol Latinoam (2008) 0.77
[Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection]. Enferm Infecc Microbiol Clin (2013) 0.76
[Epidemiology of HCV infection in Argentina]. Acta Gastroenterol Latinoam (2006) 0.76
[Recommendations for the treatment of chronic genotype 1 hepatitis C virus infection]. Acta Gastroenterol Latinoam (2012) 0.76
Latin American Association for the Study of the Liver Practice Guidelines. Diagnosis, management, and treatment of hepatitis C. Ann Hepatol (2010) 0.76
PHS guidelines for management of occupational exposure to HBV, HCV and HIV: HIV postexposure prophylaxis regimens. Am Fam Physician (2002) 0.75